Company / R&D Expense
Monte Rosa Therapeutics, Inc. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$121.6M
FY2024
5-year range
$24.0M / $121.6M
FY2020-FY2024
Trend
+9.2%
vs FY2023
Sector context
#121 of 210
Health Care
What the data says
At $122M, Monte Rosa Therapeutics, Inc.'s r&d expense ranks #121 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $24M in FY2020 to $122M in FY2024.
Based on SEC 10-K filings.
$122M in FY2024 with a 3-year CAGR of +28.6%.
Improved from $85M to $122M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +28.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#121 of 210 in Health CareTop 58% of 210This company $121.6M Sector average $644.1M
▼
-81.1% below sector average
Key checks
Key Insights
- Monte Rosa Therapeutics, Inc.'s r&d expense has grown for 4 consecutive years.
- 3-year CAGR of +28.6%, indicating consistent growth.
- In FY2024, r&d expense increased 9.2% year-over-year.
- Ranks #121 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $121.6M | +9.2% |
| FY2023 | $111.3M | +30.8% |
| FY2022 | $85.1M | +48.8% |
| FY2021 | $57.2M | +138.1% |
| FY2020 | $24.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026